Conference Coverage

VIDEO: Lyme disease spreading, but better testing may be coming


 

EXPERT ANALYSIS AT CCR 18

SANDESTIN, FLA. – Lyme disease is spreading in the United States, which makes it a high priority for rheumatologists, who will need to care for an increasing number of patients with posttreatment disorders affecting the joints, an expert said at the annual Congress of Clinical Rheumatology.

Sheila Arvikar, MD, an instructor in the rheumatology division at Harvard Medical School, Boston, said that the disease – the most common vector-borne illness in the United States – is no longer strictly confined to the U.S. Northeast and the upper Midwest, according to reports from the Centers for Disease Control and Prevention. Neighboring areas are increasingly affected, the reports have shown.

The video associated with this article is no longer available on this site. Please view all of our videos on the MDedge YouTube channel.


That the disease may be spreading makes the need for awareness and better testing more acute, she said. Current testing is limited by a lack of sensitivity in early disease, and the standard two-tier combination of enzyme-linked immunosorbent assay and Western blot can be time consuming. But recent studies have found that whole cell sonicate ELISA combined with an ELISA for peptide C6 are equally or even more effective than the more cumbersome, two-tier version, Dr. Arvikar said.

A problem encountered by rheumatologists are patients who contracted Lyme disease but who continue to have joint pain and other symptoms despite treatment for the disease. This so-called posttreatment Lyme disease syndrome (PTLDS) can be similar to fibromyalgia or chronic fatigue syndrome, involving chronic symptoms but no chronic infection and no objective synovitis or inflammation.

There are no Food and Drug Administration–approved treatments for it, but options such as tricyclics, serotonin norepinephrine reuptake inhibitors, gabapentin, and pregabalin can be helpful, she said, along with exercise and cognitive-behavioral therapy. She also noted myriad alternative treatments marketed for PTLDS that have not been shown to be effective and can even be harmful, such as urine ingestion and treatment with bee venom.


“These patients are really desperate for anything to help with their symptoms, and there are lot of people out there who are preying on them with these therapies that aren’t really helpful. It’s important for us to be aware that these things are out there.”

Dr. Arvikar reported having no financial disclosures.

SOURCE: Arvikar S, CCR 2018.

Recommended Reading

AbbVie, Samsung Bioepis settle suits with delayed U.S. entry for adalimumab biosimilar
MDedge Rheumatology
Dermatology practice gaps: improving medication management
MDedge Rheumatology
Upadacitinib for RA shows encouraging results in phase 3 trial
MDedge Rheumatology
MACE risk similar across arthritis subtypes
MDedge Rheumatology
FDA advisory committee recommends baricitinib 2 mg to treat rheumatoid arthritis
MDedge Rheumatology
FDA advisory committee votes to recommend update to celecoxib safety labeling
MDedge Rheumatology
Aim for remission, not low disease activity, in rheumatoid arthritis
MDedge Rheumatology
Obesity and weight loss both linked to RA disability
MDedge Rheumatology
Methotrexate-induced pulmonary fibrosis risk examined in 10-year study
MDedge Rheumatology
VIDEO: Big Data, self-diagnosis to play role in future of RA, expert says
MDedge Rheumatology